Outcomes of BTD vs. BCD as initial treatment of renal amyloid light-chain amyloidosis: a retrospective cohort study in China

Outcomes of BTD vs. BCD as initial treatment of renal amyloid light-chain amyloidosis: a retrospective cohort study in China

Objectives To compare the efficacy and safety of bortezomib with thalidomide and dexamethasone (BTD) and bortezomib with cyclophosphamide and dexamethasone (BCD) as the initial treatment for renal amyloid light chain (AL) amyloidosis in Chinese cohort.Methods A cohort of 174 patients with AL amyloid...

Full description

Saved in:
Bibliographic Details
Main Authors: Sheng Li, Weiting He, Hok-him Yau, Jianteng Xie, Yaxi Zhu, Xiaojie Chen, Shaogui Zhang, Yifan Zhang, Pengjun Liao, Hui Liu, Liwen Li, Liye Zhong, Wenjian Wang
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Renal Failure
Subjects:
Light chain amyloidosis
bortezomib
cyclophosphamide
thalidomide
dexamethasone
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2025.2453006
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/0886022X.2025.2453006

Similar Items